Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.60 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468664 | 0.95 | MEN1 (0.65) | OXER1KMT2AMEN1ALOX5MAPT | |
| SCHEMBL29729032 | 0.87 | OXER1 (0.60) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL7718097 | 0.87 | MEN1 (0.77) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL29926431 | 0.87 | OXER1 (0.60) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL2905098 | 0.87 | MEN1 (0.77) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL5579185 | 0.87 | MEN1 (0.77) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL4329512 | 0.87 | MEN1 (0.77) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL8746346 | 0.87 | MEN1 (0.77) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL5579187 | 0.87 | MEN1 (0.77) | LTB4R2OXER1KMT2AMEN1ALOX5 | |
| SCHEMBL4329518 | 0.87 | MEN1 (0.77) | LTB4R2OXER1KMT2AMEN1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130217771-A1 | RESOLVINS: BIOEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2013-08-22 | — | — | US | disclosed |
| EP-2216318-A2 | Resolvins: Biotemplates for therapeutic interventions | BRIGHAM AND WOMEN'S HOSPITAL (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100016432-A1 | RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2010-01-21 | — | — | US | disclosed |
| US-7585856-B2 | Resolvins: Biotemplates for novel therapeutic interventions | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217771-A1 | RESOLVINS: BIOEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS | PTGES3, ALOX5, PTGES2 | LTB4R2 14/4885OXER1 547/4885KMT2A 4764/4885 |
| US-20100016432-A1 | RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS | ALOX5, PTGES3, PTGES2 | LTB4R2 13/4885OXER1 634/4885KMT2A 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.